Bioresorbable Scaffold: The Advent of a New Era in Percutaneous Coronary and Peripheral Revascularization?
暂无分享,去创建一个
[1] Frits Mastik,et al. Incidence of High-Strain Patterns in Human Coronary Arteries: Assessment With Three-Dimensional Intravascular Palpography and Correlation With Clinical Presentation , 2004, Circulation.
[2] A Haverich,et al. Left main coronary artery fistula exiting into the right atrium , 2003, Heart.
[3] Patrick Hunziker,et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.
[4] M. Vert. Bioabsorbable polymers in medicine: an overview. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[5] Patrick W Serruys,et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.
[6] W. Edwards,et al. Differential histopathology of primary atherosclerotic and restenotic lesions in coronary arteries and saphenous vein bypass grafts: analysis of tissue obtained from 73 patients by directional atherectomy. , 1991, Journal of the American College of Cardiology.
[7] Joseph Kost,et al. Handbook of Biodegradable Polymers , 1998 .
[8] J. Margolis,et al. Hideo Tamai memorial , 2009 .
[9] I. Palacios,et al. Coronary stenting decreases restenosis in lesions with early loss in luminal diameter 24 hours after successful PTCA. , 1995, Circulation.
[10] J. English,et al. Polyglycolide and polylactide , 1998 .
[11] Bernard Chevalier,et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. , 2011, Journal of the American College of Cardiology.
[12] M. Zwahlen,et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. , 2008, Journal of the American College of Cardiology.
[13] G L Kimmel,et al. Aliphatic polyesters II. The degradation of poly (DL-lactide), poly (epsilon-caprolactone), and their copolymers in vivo. , 1981, Biomaterials.
[14] Benno J. Rensing,et al. Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up , 2001, Circulation.
[15] S. Hossainy,et al. Modeling of degradation and drug release from a biodegradable stent coating. , 2007, Journal of biomedical materials research. Part A.
[16] K. Robinson,et al. Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[17] W Siegenthaler,et al. Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. , 1987, The New England journal of medicine.
[18] Michael Joner,et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.
[19] Bernard Chevalier,et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus‐eluting coronary stent and the everolimus‐eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[20] Johan Lindbäck,et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. , 2007, The New England journal of medicine.
[21] Antonio Colombo,et al. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. , 2010, Journal of the American College of Cardiology.
[22] A. Maseri,et al. Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. , 1999, Journal of the American College of Cardiology.
[23] P D Verdouw,et al. Development of a polymer endovascular prosthesis and its implantation in porcine arteries. , 1992, Journal of interventional cardiology.
[24] Karl-Heinz Waldmann,et al. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[25] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[26] P W Serruys,et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. , 1988, Circulation.
[27] A. Takeshita,et al. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. , 1993, The New England journal of medicine.
[28] Raimund Erbel,et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial , 2007, The Lancet.
[29] J. Sixma,et al. Thrombogenicity of the human arterial wall after interventional thermal injury. , 1996, Journal of vascular research.
[30] E J Topol,et al. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. , 1997, Journal of the American College of Cardiology.
[31] B Meier,et al. Restenosis after successful coronary angioplasty in patients with single-vessel disease. , 1986, Circulation.
[32] William Wijns,et al. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. , 2007, Circulation.
[33] C. G. Pitt,et al. Modification of the rates of chain cleavage of poly(ϵ-caprolactone) and related polyesters in the solid state , 1987 .
[34] Patrick W Serruys,et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. , 2005, Journal of the American College of Cardiology.
[35] O. Hess,et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. , 2005, Journal of the American College of Cardiology.
[36] F Joffre,et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. , 1987, The New England journal of medicine.
[37] P. Serruys,et al. Late Stent Thrombosis: A Nuisance in Both Bare Metal and Drug-Eluting Stents , 2007 .
[38] H. Uehata,et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. , 2000, Circulation.
[39] P. Serruys,et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[40] David Rotger,et al. Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. , 2008, Journal of the American College of Cardiology.
[41] P. Serruys,et al. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. , 1994, American heart journal.
[42] M. Leon,et al. Remodeling of human coronary arteries undergoing coronary angioplasty or atherectomy. , 1997, Circulation.
[43] L. Pendyala,et al. The first-generation drug-eluting stents and coronary endothelial dysfunction. , 2009, JACC. Cardiovascular interventions.
[44] Antonio Colombo,et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.
[45] A. Schindler,et al. Aliphatic polyesters. I. The degradation of poly(ϵ‐caprolactone) in vivo , 1981 .
[46] Raimund Erbel,et al. Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. , 2009, JACC. Cardiovascular interventions.
[47] P. Serruys,et al. Characterizing Vulnerable Plaque Features With Intravascular Elastography , 2003, Circulation.
[48] E. Topol,et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. , 1996, Circulation.
[49] M. Nobuyoshi,et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. , 1988, Journal of the American College of Cardiology.
[50] J O Hollinger,et al. Biodegradable bone repair materials. Synthetic polymers and ceramics. , 1986, Clinical orthopaedics and related research.
[51] R. Erbel,et al. Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[52] Michael Joner,et al. Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[53] Jeffrey J. Popma,et al. Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study , 2001, Circulation.
[54] C von Birgelen,et al. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. , 1995, The American journal of cardiology.
[55] J F Orr,et al. Degradation of poly-L-lactide. Part 1: in vitro and in vivo physiological temperature degradation , 2004, Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine.
[56] P. Serruys,et al. Biodegradable stents and non-biodegradable stents. , 2009, Minerva cardioangiologica.
[57] Neville Kukreja,et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.
[58] H. M. Payne,et al. Validation of A Doppler Guide Wire for Intravascular Measurement of Coronary Artery Flow Velocity , 1992, Circulation.
[59] M. Leon,et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. , 1996, Circulation.
[60] M. Fishbein,et al. Coronary artery restenosis after balloon angioplasty in humans is associated with circumferential coronary constriction. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[61] G. D. De Meyer,et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. , 2007, Journal of the American College of Cardiology.
[62] Richard L. Kronenthal,et al. BIODEGRADABLE POLYMERS IN MEDICINE AND SURGERY , 1975 .
[63] M. Leon,et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. , 1996, Circulation.
[64] C Vallbracht,et al. Recurrence rate after successful coronary angioplasty. , 1985, European heart journal.
[65] William Wijns,et al. A Cause for Concern , 2007 .
[66] Janita F. J. Vos,et al. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. , 2001, European heart journal.
[67] F. Verheugt,et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. , 2009, Journal of the American College of Cardiology.
[68] Ousa,et al. A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .
[69] R. Virmani,et al. Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.
[70] P. Serruys,et al. Quantitative multi-modality imaging analysis of a bioabsorbable poly-L-lactic acid stent design in the acute phase: a comparison between 2- and 3D-QCA, QCU and QMSCT-CA. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[71] P. Serruys,et al. Three‐dimensional and quantitative analysis of atherosclerotic plaque composition by automated differential echogenicity , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[72] Patrick W Serruys,et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.
[73] S. Pocock,et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. , 2007, European heart journal.
[74] Matthias Stuber,et al. Artifact-Free Coronary Magnetic Resonance Angiography and Coronary Vessel Wall Imaging in the Presence of a New, Metallic, Coronary Magnetic Resonance Imaging Stent , 2005, Circulation.
[75] K. Robinson,et al. Novel bioabsorbable salicylate‐based polymer as a drug‐eluting stent coating , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[76] P. Serruys,et al. Late coronary occlusion after intracoronary brachytherapy. , 1999, Circulation.
[77] H Shimokawa,et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. , 1998, Journal of the American College of Cardiology.
[78] J F Orr,et al. Degradation of poly-L-lactide. Part 2: Increased temperature accelerated degradation , 2004, Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine.
[79] A. Quyyumi,et al. Prognostic Value of Coronary Vascular Endothelial Dysfunction , 2002, Circulation.
[80] M. Reidy,et al. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. , 1983, Laboratory investigation; a journal of technical methods and pathology.
[81] J. Oldenburg,et al. Hemophilia A Patients with Undetectable Mutations: Current Knowledge and Future Directions* , 2006, Transfusion Medicine and Hemotherapy.
[82] W Rutsch,et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.
[83] H. Shimokawa,et al. Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. , 2000, Japanese circulation journal.
[84] Bernard Chevalier,et al. Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes , 2010, Circulation.
[85] P. Serruys,et al. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[86] Simon Wandel,et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.
[87] Yoshinobu Onuma,et al. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: An OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial , 2010 .
[88] P. Teirstein,et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.
[89] R. Rapoza,et al. Design principles and performance of bioresorbable polymeric vascular scaffolds. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[90] Patrick W Serruys,et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2009, The Lancet.
[91] Bernd Heublein,et al. Preliminary Results after Application of Absorbable Metal Stents in Patients with Critical Limb Ischemia , 2005, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.
[92] S. Higano,et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. , 2000, Circulation.
[93] R. Kronenthal,et al. Polymers in medicine and surgery , 1975 .
[94] W. Siegenthaler,et al. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. , 1979, The New England journal of medicine.
[95] P. Serruys,et al. A comparison of two methods to measure coronary flow reserve in the setting of coronary angioplasty: intracoronary blood flow velocity measurements with a Doppler catheter, and digital subtraction cineangiography. , 1989, European heart journal.
[96] S. Lobodzinski,et al. Bioabsorbable coronary stents. , 2008, Cardiology journal.
[97] M. Nobuyoshi,et al. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. , 1991, Journal of the American College of Cardiology.
[98] R. Waksman,et al. Late thrombosis after radiation. Sitting on a time bomb. , 1999, Circulation.
[99] P. Serruys,et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. , 2006, European heart journal.
[100] P. Hunold,et al. Images in cardiovascular medicine. Novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. , 2005, Circulation.